PINES: Eltrombopag achieves superior platelet responses versus SoC in pediatric patients with immune thrombocytopenia

Further Publications

Efficacy of thrombopoietin receptor agonists versus rituximab in non-responsive immune thrombocytopenia-A single centre retrospective analysis

Br J Haematol

Stolz SM, Schwotzer R, Rösler W, Hofer KD, Balabanov S, Manz MG, Rieger MJ

doi: 10.1111/bjh.19629

Lymphoma

Real-World Direct Comparison Shows Superiority of Axi-Cel over Liso-Cel in Patients with R/R LBCL

ASH 2024

Leukemia

AMPLIFY: Superior PFS with acalabrutinib plus venetoclax with or without obinutuzumab versus chemoimmunotherapy in patients with treatment-naïve CLL

Lymphoma

Robust CAR T-cell expansion and superior outcomes in DLBCL patients in complete response at infusion

Br J Haematol

Hanajiri R, Wakabayashi H, Ishigiwa K, Ohara F, Hirano S, Yokota H, Kuwano S, Furukawa K, Shimada K, Sato T, Terakura S, Kiyoi H

doi: 10.1111/bjh.20186

Further Publications

Real-world response assessment of immune checkpoint inhibition: comparing iRECIST and RECIST 1.1 in melanoma and non-small cell lung cancer patients

Eur Radiol

Nelles C, Gräf M, Bernard P, Persigehl T, Große Hokamp N, Zopfs D, Maintz D, Kreuzberg N, Wolf J, Bröckelmann PJ, Lennartz S

doi: 10.1007/s00330-024-11060-4

Multiple Myeloma (MM)

Prognostic value of minimal residual disease detected by EuroFlow next-generation flow cytometry and next-generation sequencing in patients with multiple myeloma achieving complete response and receiving lenalidomide maintenance after autotransplant: a prospective comparison study

Haematologica

Yoroidaka T, Takamatsu H, Urushihara R, Itagaki M, Yoshihara S, Sato K, Takezako N, Ozaki S, Suzuki K, Kohno K, Muta T, Matsumoto M, Terasaki Y, Yamashita T, Fuchida SI, Sakamoto J, Ishida T, Suzuki K, Murakami H, Durie BGM, Shimizu K

doi: 10.3324/haematol.2025.287411

Further Publications

Circulating tumor DNA Clearance as a Predictive Biomarker of Pathologic Complete Response in Patients with Solid Tumors Treated with Neoadjuvant Immune-Checkpoint Inhibitors: a Systematic Review and Meta-Analysis

Ann Oncol

Valenza C, Saldanha EF, Gong Y, De Placido P, Gritsch D, Ortiz H, Trapani D, Conforti F, Cremolini C, Peters S, Mateo J, Subbiah V, Parsons HA, Partridge AH, Curigliano G

doi: 10.1016/j.annonc.2025.03.019

Genitourinary Cancer

Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3 TiNivo-2 Study

Lancet

Choueiri TK, Albiges L, Barthélémy P, Iacovelli R, Emambux S, Molina-Cerrillo J, Garmezy B, Barata P, Basu A, Bourlon MT, Moon H, Ratta R, McKay RR, Chehrazi-Raffle A, Hammers H, Heng DYC, Braendle E, Beckermann KE, McGregor BA, Motzer RJ

doi: 10.1016/S0140-6736(24)01758-6

Genitourinary Cancer

Clinical features and response to immune combinations in patients with renal cell carcinoma and sarcomatoid de-differentiation (ARON-1 study)

Int J Cancer

Ciccarese C, Büttner T, Cerbone L, Zampiva I, Monteiro FSM, Basso U, Pichler M, Vitale MG, Fiala O, Roviello G, Kopp RM, Carrozza F, Pichler R, Grillone F, Calabuig EP, Zeppellini A, Küronya Z, Galli L, Facchini G, Sunela K, Mosca A, Molina-Cerrillo J, Spinelli GP, Ansari J, Scala A, Mollica V, Grande E, Buti S, Kanesvaran R, Zakopoulou R, Bamias A, Rizzo M, Massari F, Iacovelli R, Santoni M

doi: 10.1002/ijc.35141

Related content

Efficacy of thrombopoietin receptor agonists versus rituximab in non-responsive immune thrombocytopenia-A single centre retrospective analysis

Real-World Direct Comparison Shows Superiority of Axi-Cel over Liso-Cel in Patients with R/R LBCL

AMPLIFY: Superior PFS with acalabrutinib plus venetoclax with or without obinutuzumab versus chemoimmunotherapy in patients with treatment-naïve CLL

Robust CAR T-cell expansion and superior outcomes in DLBCL patients in complete response at infusion

Real-world response assessment of immune checkpoint inhibition: comparing iRECIST and RECIST 1.1 in melanoma and non-small cell lung cancer patients

Prognostic value of minimal residual disease detected by EuroFlow next-generation flow cytometry and next-generation sequencing in patients with multiple myeloma achieving complete response and receiving lenalidomide maintenance after autotransplant: a prospective comparison study

Circulating tumor DNA Clearance as a Predictive Biomarker of Pathologic Complete Response in Patients with Solid Tumors Treated with Neoadjuvant Immune-Checkpoint Inhibitors: a Systematic Review and Meta-Analysis

Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3 TiNivo-2 Study

Clinical features and response to immune combinations in patients with renal cell carcinoma and sarcomatoid de-differentiation (ARON-1 study)